-
Recent Posts
- Dementia-Friendly Communities Provision, Viewed as a Social Determinant of Health (JGCR / NHS England / WHO)
- International Perspectives on the Possible Impact of the COVID-19 Pandemic and Lockdown on Abuse of the Elderly (JGCR / American Journal of Geriatric Psychiatry / JAGS)
- Updates Relating to the Lancet Commission on Dementia Prevention, Intervention, and Care (Lancet / Alzheimer’s Research and Therapy / Alzheimer’s and Dementia)
- A Brief Review of How the COVID-19 Pandemic Relates to Elderly Care and Research (JGCR)
- Some Speculated / Potential Benefits of COVID-19 (JGCR / BBC Radio 4’s Rethink / BGS)
Archives
- September 2020
- August 2020
- June 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Alzheimer’s Prevention Initiative Study
Summary of Recent Progress in Alzheimer’s Disease Prevention Trials (CTAD / JPAD)
Summary The following article summarises a round-up of present understanding and developments reflected in current and planned prevention trials, as discussed at a EU / US / Clinical Trials in Alzheimer’s Disease (CTAD) Task Force meeting, as of December 2016-7. … Continue reading →
Posted in For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Quick Insights
|
Tagged Accelerating Alzheimer's Research and Drug Development, Alzheimer's Disease Co-operative Study - Activities of Daily Living Scale (ADCS-ADL), Alzheimer’s Disease Prevention Trials, Alzheimer’s Prevention Initiative (API), Alzheimer’s Prevention Initiative Study, Alzheimer’s Therapeutic Research Institute (ATRI), Amsterdam IADL Questionnaire, Amyloid and Tau Imaging, Amyloid and Tau PET, Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) Study, Banner Alzheimer's Institute (Arizona), Biological Markers, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Blood Proteins as Biomarkers of Disease Research, Blood-Based Biomarkers, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, Brigham and Women's Hospital, Canada, CHU Toulouse (France), Cognitive Function Instrument, Cognitive Outcome Measures, Cogstate iPad C3 Battery, Collaboration for Alzheimer’s Prevention (CAP), Composite Measures (sic Cognitive Composites), Conversion to Dementia From Prodromal Disease, Dementia Prevention, Dementia Research and Drug Development, Dementia Risk Prevention, Dementia Risk Reduction and Prevention, Denali Therapeutics (South San Francisco), Department of Epidemiology and Public Health: CHU Toulouse, DIAN-TU Study, DIAN-TU Trial, Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), Dominantly Inherited Alzheimer’s Network Trials Unit (DIAN-TU), Drug Development for Alzheimer's Disease, Drug-Development Pipeline, EU/US/Clinical Trials in Alzheimer's Disease (CTAD) Task Force, EU/US/Clinical Trials in Alzheimer's Disease (CTAD) Task Force (December 2016 Meeting), European Medicines Agency, Everyday Cognition (E-Cog) Scale, F-31073 (Toulouse), F. Hoffmann-LaRoche Ltd (Basel), France, Free and Cued Selective Reminding Test (FCSRT), Functional Activities Questionnaire (FAQ), Gerontopole Toulouse: Toulouse University Hospital, Global R&D Partners LLC (San Diego), Harvard Medical School, Imaging, Inc. (New York), Informant-Reported Outcome Measures, Innovation Infrastructure, Johns Hopkins University School of Medicine Baltimore, Journal of Prevention of Alzheimer’s Disease (JPAD), Keck School of Medicine: University of Southern California, Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) Study, McGill University, Molecular Imaging; Mild Behavioral Impairment, Multi-Domain Alzheimer’s Prevention Trial (MAPT), National Institutes of Health’s Accelerating Medicines Partnership (AMP), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Neurology (FDA), Next Generation (NexGen) Prevention Trial, NIH Toolbox Cognition Battery (NIHTB-CB), Non-Invasive Biomarkers, Outcome Measures, Participation in Research, Patient Reported Outcome Measures, Pentara Corporation (Salt Lake City), PET, Pfizer, Plasma Biomarkers, Preclinical Alzheimer's Disease, Preclinical Alzheimer’s Cognitive Composite (PACC), Preclinical Biomarkers and Dementia, Preclinical Biomarkers in Alzheimer's Disease, Preclinical Indicators and Dementia, Preclinical Indicators in Alzheimer's Disease, Prevention, Prevention Agenda, Prevention Agenda Linking Dementia and Other Non-Communicable Diseases, Prevention Approaches, Prodromal Alzheimer's Disease, Promisary Science, Recruitment and Retention, Regulation and Drug Development For Early-Stage Alzheimer's Disease, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Mapping, Research Networks, Research Promotion, Sharing Knowledge and Information, Slowing Progression of Disease (Stabilisation), Switzerland, Tau PET, Technology and Infrastructure Development, TOMMORROW Study, UMR1027 Inserm, United States, University College London, University Hospital of Montpellier, University of Southern California, University of Toulouse III, USA, Washington University School of Medicine
|
Leave a comment
Developments in Dementia Research: From the Horses’ Mouths (NHS England / NIHR)
Summary Professor Alistair Burns (NHS England’s National Clinical Director for Dementia and Older Peoples’ Mental Health), and Professor Martin Rossor (NIHR National Director for Dementia Research), discuss current issues and new approaches in dementia research, touching briefly upon some of … Continue reading →
Posted in For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Mental Health, Models of Dementia Care, National, NHS England, NIHR, Pharmacological Treatments, Quick Insights, UK, Universal Interest
|
Tagged 100000 Genomes Project, A4 Study, Alistair Burns: Honorary Consultant Old Age Psychiatrist in the Manchester Mental Health and Social Care Trust (MMHSCT), Alistair Burns: NHS England’s National Clinical Director for Older People’s Mental Health, Alistair Burns: Professor of Old Age Psychiatry at University of Manchester, Alzheimer's Prevention Initiative, Alzheimer’s Disease Biomarkers, Alzheimer’s Prevention Initiative Study, Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Study (A4 Study), APP and Presenilin, Asymptomatic Alzheimer’s Disease, Banner Alzheimer's Institute, Biomarkers, Chance Genetic Mutations, Colombia, Colombian Alzheimer's Prevention Initiative Registry in Medellín Antioquia, DIAN-TU Study, DIAN-TU Trial, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), Early Detection of Alzheimer’s Disease, Early Detection of Preclinical Disease, Genentech, Genomics, Genomics England, Genomics in the NHS, Genomics-Based Medicine, Global Outlook, Identification of People At Risk of Dementia, International Collaborations, International Programmes, International Research, Medellin (Colombia), Monoclonal Antibodies, MRC Neurochemical Pharmacology Unit, Mutational Signatures, National Clinical Director for Dementia, National Institute for Health Research (NIHR), National Institutes of Health (NIH), National Institutes of Health (US), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, NIHR Clinical Research Network, NIHR Dementia Translational Research Collaboration, NIHR National Director for Dementia Research, NIHR Translational Research Collaboration, Overcoming Barriers, Participation in Research, Participation in Research Studies, Preclinical Alzheimer's Disease, Presenilin, Prodromal Alzheimer's Disease, Professor Alistair Burns, Professor Martin Rossor: Director of the NIHR Queen Square Dementia Biomedical Research Unit, Professor Martin Rossor: Former Director of the NIHR Dementia and Neurodegenerative Disease Research Network (DeNDRoN), Professor Martin Rossor: Former President of the Association of British Neurologists (2011-2013), Professor Martin Rossor: Honorary Consultant Neurologist at National Hospital for Neurology and Neurosurgery, Professor Martin Rossor: National Hospital (Queen Square), Professor Martin Rossor: NIHR National Director for Dementia Research, Professor Martin Rossor: UCL Institute of Neurology, Promisary Science, Reducing Downstream Effects of Disease, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Mapping, Research Networks, Research Promotion, Sharing Knowledge and Information, Slowing Progression of Disease (Stabilisation), Solanezumab (Sola or Solab), Solanezumab: Humanised Monoclonal Antibody, Therapeutic Nihilism (Avoiding), Translational Research, UK Genomes Project: Genomics England, University of Southern California’s Alzheimer’s Therapeutic Research Institute, Washington University School of Medicine
|
Leave a comment
